STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLXN
  4. [Form 4] Silexion Therapeutics Corp Insider Trading Activity

Silexion (SLXN) CEO Hadar Ilan receives 64,350-share equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hadar Ilan reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp Chairman and CEO Hadar Ilan received a grant of 64,350 fully vested restricted share units that were immediately settled into ordinary shares at a price of $0.0000 per share, as compensation for officer services and approved by the board. Following this award, Ilan directly holds 65,471 ordinary shares. The filing also lists 956 stock options to buy ordinary shares for informational purposes only, with no new option transaction reported.

Positive

  • None.

Negative

  • None.
Insider Hadar Ilan
Role Chairman and CEO
Type Security Shares Price Value
Grant/Award Ordinary Shares 64,350 $0.00 --
holding Stock Option (right to buy Ordinary Shares) -- -- --
Holdings After Transaction: Ordinary Shares — 65,471 shares (Direct); Stock Option (right to buy Ordinary Shares) — 956 shares (Direct)
Footnotes (1)
  1. The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflects adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The number of options to purchase ordinary share and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hadar Ilan
(Last) (First) (Middle)
C/O SILEXION THERAPEUTICS CORP
12 ABBA HILLEL ROAD
(Street)
RAMAT GAN L3 5250606
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 02/20/2026 A(2) 64,350 A $0 65,471 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy Ordinary Shares)(3) $907.71(4) 08/15/2024 03/24/2032 Ordinary Shares 956(4) 956 D
Explanation of Responses:
1. The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflects adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.
2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
4. The number of options to purchase ordinary share and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
/s/ Mirit Horenshtein Hadar, Attorney-in-fact 02/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Silexion Therapeutics (SLXN) report for Hadar Ilan?

Silexion Therapeutics reported that Chairman and CEO Hadar Ilan received 64,350 fully vested restricted share units, immediately settled into ordinary shares. The grant was compensation for officer services and was approved by the company’s board of directors.

How many Silexion Therapeutics (SLXN) shares does Hadar Ilan hold after the latest grant?

After the latest equity award, Hadar Ilan directly holds 65,471 ordinary shares of Silexion Therapeutics. This reflects the addition of 64,350 fully vested restricted share units that were immediately converted into ordinary shares for his officer services.

Was cash involved in the Silexion Therapeutics (SLXN) equity grant to Hadar Ilan?

The equity grant to Hadar Ilan had a reported price of $0.0000 per ordinary share, indicating it was a stock-based compensation award rather than a cash purchase. The grant consisted of fully vested restricted share units settled into ordinary shares.

What type of equity award did Silexion Therapeutics (SLXN) give its CEO on February 20, 2026?

On February 20, 2026, Silexion Therapeutics granted its CEO Hadar Ilan fully vested restricted share units that immediately settled into 64,350 ordinary shares. The award was given for his services as an officer and approved by the board.

Does the Form 4 for Silexion Therapeutics (SLXN) show any new stock option transactions?

The Form 4 lists 956 stock options to buy ordinary shares as a holding but states there were no transactions in these securities. The option information is included only for informational purposes, with no newly executed option trades reported.

Did prior reverse share splits affect the Silexion Therapeutics (SLXN) share counts in this Form 4?

Yes. The share and option amounts in the Form 4 reflect adjustments for 1-for-9 and 1-for-15 reverse share splits that Silexion Therapeutics implemented on November 29, 2024 and July 29, 2025, respectively, affecting reported ordinary share and option figures.